SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

AGM Statement

19 Dec 2023 07:00

RNS Number : 1950X
Tristel PLC
19 December 2023
 

Tristel plc

("Tristel", the "Company", or the "Group")

AGM Statement, notice of results and planned CEO succession

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at the offices of Cavendish, One Bartholomew Close, London EC1A 7BL.

 

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

 

"I am pleased to report that the Company has had a record first half with revenue for the six months ending 31 December 2023 expected to be £20.7m, an increase of 18% compared to £17.5m in the first half of last year. Revenue growth has been delivered across all our geographical markets. Gross margin remains above 80% in line with our expectations.

 

"In the United States, Parker Laboratories, our manufacturing and distribution partner, completed its first production run for Tristel ULT in early October, following receipt of our FDA approval in June 2023. This has enabled Parker to stock its national distribution network and provide product to the first beta site users. We expect to make steady progress in building our customer base throughout the United States during the second half of our financial year. We remain very excited about our prospects as we begin serving the largest healthcare market in the world.

 

"The business is performing strongly on all fronts and the confidence that we expressed in October in our medium-term outlook remains unchanged. With the growth possibilities for our business stronger than ever, and as a business with no debt and forecast cash balances of approximately £10.4m after payment of this year's final dividend on 22 December, we are in a strong position to capitalise upon our global leadership position in the medical device decontamination market." 

 

Notice of Results

The Company's unaudited interim results will be announced on 26 February 2024.

 

CEO succession planning

In addition, Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates.

 

The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Charlotte Edgar

Mob: 07884 664 686

Alice Woodings

Mob: 07407 804 654

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash/Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEVLFFXLLXFBL
Date   Source Headline
22nd May 201511:19 amRNSIssue of Equity
21st May 20157:00 amRNSTrading update
8th May 20157:00 amRNSIssue of Equity
4th Mar 20157:00 amRNSIssue of Equity/Director dealing
26th Feb 20157:01 amRNSInvestor Presentation
25th Feb 20157:00 amRNSHalf Yearly Report
6th Feb 20157:00 amRNSInvestor Results Presentation
28th Jan 20157:00 amRNSIssue of Equity
24th Dec 201411:27 amRNSGrant of Share Options
23rd Dec 20142:38 pmRNSDirector/PDMR Shareholding
16th Dec 201411:53 amRNSResult of AGM
16th Dec 20147:00 amRNSAGM Statement
21st Nov 20147:00 amRNSPosting of Annual Report & Notice of AGM
17th Nov 20143:27 pmRNSIssue of Equity
11th Nov 20147:00 amRNSNZ ENT study shows Tristel Wipes System benefits
3rd Nov 20146:02 pmRNSDirector's Shareholding
20th Oct 201411:56 amRNSIssue of Equity
13th Oct 20147:00 amRNSFinal Results
29th Sep 20147:00 amRNSInvestor Results Presentation
19th Aug 20147:00 amRNSMarket leadership in UK ENT market
28th Jul 20147:00 amRNSPre-close trading update
7th Jul 201410:03 amRNSIssue of Equity
23rd Jun 20148:30 amRNSIssue of Equity
18th Jun 201411:16 amRNSHolding(s) in Company
10th Jun 20147:00 amRNSTrading Update
22nd May 201412:37 pmRNSIssue of Equity
28th Apr 20147:00 amRNSTrading update
24th Apr 20147:00 amRNSSuccess in controlling Clostridium difficile rates
13th Mar 20147:00 amRNSPublic Health England tackle disease threats
3rd Mar 20147:01 amRNSGrant of Share Options
3rd Mar 20147:00 amRNSHalf Yearly Report
13th Feb 20147:00 amRNSInvestor Results Presentation
22nd Jan 20147:00 amRNSTrading Update and notice of results
10th Dec 20132:14 pmRNSResult of AGM
10th Dec 20137:00 amRNSAGM Statement
15th Nov 20137:00 amRNSPosting of Annual Report & Notice of AGM
18th Oct 20137:00 amRNSPeer-reviewed published article
14th Oct 20137:00 amRNSFinal Results
22nd Jul 20137:00 amRNSTrading Update & Notice of Results
28th May 20132:19 pmRNSDirector/PDMR Shareholding
29th Apr 20132:53 pmRNSHolding(s) in Company
15th Apr 20131:47 pmRNSHolding(s) in Company
10th Apr 201311:45 amRNSHolding(s) in Company
9th Apr 201311:18 amRNSDirectors' Shareholdings
21st Mar 20132:44 pmRNSHolding(s) in Company
4th Mar 20139:28 amRNSDirector Shareholding
4th Mar 20137:00 amRNSHalf Yearly Report
14th Feb 20137:00 amRNSTrading update and notice of results
18th Jan 20137:00 amRNSTristel Wipes System obtains approval in China
17th Jan 20137:00 amRNSPeer-reviewed published articles

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.